Bayer highlights latest oncology research at ASCO 2018

Clinical research to be presented from Bayer’s growing oncology portfolio, including radium-223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds ...

Disappointing verdict requires in-depth analysis

General Court of the European Union decides that neonicotinoid restrictions imposed by European Commission in 2013 were lawful / Bayer will assess the verdict’s consequences and potential legal options ...

Bayer receives approval for Eylea® in China

Eylea® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration ...

CVBD® World Forum: Communication is key to managing vector-borne diesease threats in veterinary practice

Communications tools are needed to help achieve more meaningful outcomes in vector-borne disease prevention ...

Bayer announces Executive Leadership Team for new Crop Science division

Liam Condon to lead newly combined organization ...

Bayer concludes process to sell Covestro

14.2 percent interest sold for 2.2 billion euros / 6.8 percent of shares retained to repay exchangeable bond ...

Bayer initiates full separation from Covestro

Accelerated bookbuilding process started for 14.2 percent ...

Bayer: Operational business held back by currency effects – Major progress with Monsanto acquisition

Group sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros ...

Neonicotinoid ban: a sad day for farmers and a bad deal for Europe

Bayer signs agreement to sell further Crop Science businesses to BASF for up to 1.7 billion euros

Package includes global vegetable seeds business, certain seed treatments and digital farming activities ...